The randomized control period of the MINT trial has completed, and these newest data describe outcomes among patients who ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a ...

"All three types of myasthenia gravis, based on antibody status ... in appearance because of facial weakness than those with AChR-antibody positive MG." Antibodies to AChR are most common ...

Amgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna (inebilizumab) ...

EPYSQLI is designed to treat gMG in adults who are anti-acetylcholine receptor antibody positive.

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open label extension ...

J&J exhibited additional findings, displaying that nipocalimab met its key secondary endpoint, a change in QMG score.

Cartesian reports 12-month data for Descartes-08 in myasthenia gravis; Phase 3 AURORA trial expected to begin in Q2 2025.

Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major ...

Treatment with inebilizumab is significantly effective and safe for patients with AChR+ or MuSK+ generalized myasthenia ...